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Dr Daniel O Dr Daniel O’ ’Brien for the MSF  Brien for the MSF HIV/AIDS HIV/AIDS working group working groupBackground : paediatric HIV treatment Background : paediatric HIV treatment
z 2005: 2.3 million children living with HIV, 
and 300,000 needing ART. 
z Few children in RLS currently on ART
– Limited experience
– Lack of affordable simple diagnostic testing
– Lack of  affordable, adapted paediatric ARV 
formulations
– Lack of paediatric FDC
– Lack of standard paediatric dosing regimensBackground : MSF programs Background : MSF programs
z HIV/AIDS programs  65 
z Countries 32
z Patients on ART (March 2006)          57,344
z Children < 15 years on ART        4096 (7%)
z Collaboration with public health services
z Urban, semi-urban and rural settingsObjectives Objectives
z To assess treatment outcomes in children 
given ART under routine MSF program 
conditions according to baseline 
immunological status.Definitions Definitions
z Profound immunosuppression
⇒ CD4 <5%
z Severe immunosuppression
⇒ CD4 ≥5% + <15%
z Mild-moderate immunosuppression
⇒ CD4 ≥15%Methods Methods
z Multi-centric analysis of data collected using a 
standardized data collection software (FUCHIA) 
z Study period : Dec 2001 - March 2006
z Eligibility criteria
– Project ≥30 children
– Age 18-59 months
– ART and available baseline CD4 dataStudy cohort Study cohort
z Children in MSF cohort  16,077
z Children started on ART  4654 (29%)
z Study population
– Age 18-59 months on ART 1458
– Exclusion:
z Project <30 children 121
z No CD4% at baseline 581
– Total included in the analysis: 756
z 23 projects in 12 countries : 8 in Africa, 2 in 
Asia and 2 in Central AmericaBaseline characteristics by CD4%  Baseline characteristics by CD4% 
group group
Baseline CD4%
Characteristics <5%
N=101
≥5%-<15%
N= 468
≥15%
N= 187
Female  37 (37%) 215 (46%)
3.1 
{2.3-4.1}
11 
{9.8-13}
142 (30%)
178 (38%)
461 (99%)
92 (49%)
Median age yrs
{IQR}
3.6 
{2.9-4.3}
3.1 
{2.3-4.1}
Median weight kg
{IQR}
11 
{9.5-13.1}
11 
{9.5-14}
73 (42%)
65 (37%)
176 (94%)
CDC stage B       
CDC stage C
36 (36%)
42 (42%)
ARV naive 100 (99%)ART regimens ART regimens
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CD4% <5%
N=101
CD4% ≥5%-
<15%
N=468
≥15%
N=187
Median (IQR) 
months
13.3 (4.9-19.3) 10.3 (4.0-17.9)
207 (44%)
8.4 (3.1-18.4) 
≥12 months 54 (53%) 78 (42%)Outcomes by CD4% group Outcomes by CD4% group
<5%
N=101
CD4% ≥5%-
<15%
N=468
≥15%
N=187
Alive on ART 81 (80%) 392 (84%)
18 (4%)
35 (8%)
7 (2%)
12 (3%)
4 (1%)
157 (84%)
Dead 12 (12%) 6 (3%)
Lost to follow-
up
2 (2%) 11 (6%)
ART stopped 3 (3%) 3 (2%)
Transferred out 3 (3%) 9 (5%)
Unknown 0 (0%) 1 (1%)Deaths by time on ART (n=36) Deaths by time on ART (n=36)
11%
6%
6%
78%
< 6 months
6-12 months
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24-36 months
Median time on ART at death: 1.5 months (IQR 0.6 – 5.3)Survival by baseline CD4% group Survival by baseline CD4% group
(end point : deaths + LFU) (end point : deaths + LFU)
Time <5%
n=101
CD4% ≥5%-<15%
n=468
≥15%
n=187
6 months 
(95% CI)
0.89 (0.89-0.94)
n=70
0.94 (0.92-0.96)
n=315
0.91 (0.88-0.94)
n=207
0.82 (0.75-0.87)
n=54
0.93 (0.88-0.96)
n=110
12 months 
(95% CI)
0.88 (0.79-0.93)
n=54
0.91 (0.85-0.95)
n=78 
24 months 
(95% CI)
0.84 (0.73-0.91)
n=12
0.86 (0.77-0.92)
n=15Probability of  Probability of survival survival
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CD4%>15Limitations Limitations
z Surveillance multicentric data
z Relatively short follow-up 
z Limited information on immunological 
outcomes 
z No virological outcomesConclusions Conclusions
z Very satisfactory treatment outcomes for 
children with profound and severe 
immunosuppression in resource limited 
settings
z Extent immunosuppression at baseline for 
ART does not appear to impact on short-
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